Palo Alto, CA, United States of America

Andrew Mendelsohn

USPTO Granted Patents = 2 

Average Co-Inventor Count = 4.4

ph-index = 1


Company Filing History:


Years Active: 2020-2021

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Andrew Mendelsohn

Introduction

Andrew Mendelsohn is a notable inventor based in Palo Alto, California. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic and diagnostic purposes. With a total of two patents to his name, Mendelsohn's work has the potential to impact various medical conditions.

Latest Patents

Mendelsohn's latest patents include "Anti-CD79 antibodies and their uses" and "Anti-marinobufagenin antibodies and uses thereof." The first patent provides humanized and affinity matured antibodies that specifically bind to CD79 with high affinity. These antibodies can be utilized to treat antibody-associated conditions such as autoimmune diseases, allergies, and transplant rejection. Additionally, they can serve diagnostic purposes by detecting CD79 cells in biological samples. The second patent focuses on chimeric, humanized, and human monoclonal antibodies that bind to marinobufagenin (MBG) with high affinity. These antibodies are designed to treat MBG-associated disorders, including hypertensive and fibrotic disorders, and can also be used for diagnostic purposes.

Career Highlights

Throughout his career, Andrew Mendelsohn has worked with several companies, including Nepenthe Bioscience LLC and Cts Biopharma LLC. His experience in these organizations has contributed to his expertise in the development of innovative biopharmaceutical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…